You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRamipril
Accession NumberDB00178  (APRD00009)
TypeSmall Molecule
GroupsApproved
DescriptionRamipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Structure
Thumb
Synonyms
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Altace (tn)
Ramipril
Ramiprilum
Tritace
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-ramiprilCapsule5 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilCapsule10 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilCapsule1.25 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilCapsule15 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilCapsule2.5 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Act RamiprilCapsule2.5 mgOralActavis Pharma Company2007-10-02Not applicableCanada
Act RamiprilCapsule5 mgOralActavis Pharma Company2007-10-02Not applicableCanada
Act RamiprilCapsule10 mgOralActavis Pharma Company2007-10-02Not applicableCanada
Act RamiprilCapsule1.25 mgOralActavis Pharma Company2007-10-02Not applicableCanada
AltaceTablet2.5 mgOralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
AltaceCapsule10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-05-24Not applicableUs
AltaceCapsule15 mgOralValeant Canada Lp/valeant Canada s.e.c.2006-08-14Not applicableCanada
AltaceCapsule10 mg/1OralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
AltaceTablet1.25 mgOralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
AltaceCapsule5 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-04-21Not applicableCanada
AltaceCapsule1.25 mg/1OralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
AltaceTablet5 mgOralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
AltaceCapsule2.5 mg/1OralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
AltaceCapsule1.25 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-28Not applicableCanada
AltaceTablet10 mgOralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
AltaceCapsule2.5 mgOralValeant Canada Lp/valeant Canada s.e.c.1997-04-21Not applicableCanada
AltaceCapsule5 mg/1OralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
AltaceCapsule10 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-03-24Not applicableCanada
Altace Cap 1.25mgCapsule1.25 mgOralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 10mgCapsule10 mgOralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 2.5mgCapsule2.5 mgOralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 5mgCapsule5 mgOralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Auro-ramiprilCapsule5 mgOralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilCapsule10 mgOralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilCapsule1.25 mgOralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilCapsule2.5 mgOralAuro Pharma Inc2012-09-13Not applicableCanada
Ava-ramiprilTablet10 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramiprilTablet1.25 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramiprilTablet2.5 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramiprilTablet5 mgOralAvanstra Inc2011-09-192014-08-21Canada
Bio-ramiprilCapsule2.5 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-ramiprilCapsule5 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-ramiprilCapsule10 mgOralBiomed PharmaNot applicableNot applicableCanada
Dom-ramiprilCapsule10 mgOralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilCapsule1.25 mgOralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilCapsule2.5 mgOralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilCapsule5 mgOralDominion Pharmacal2010-06-01Not applicableCanada
Ipg-ramiprilCapsule1.25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilCapsule15 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilCapsule2.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilCapsule5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilCapsule10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-ramiprilCapsule10 mgOralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilCapsule1.25 mgOralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilCapsule2.5 mgOralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilCapsule15 mgOralJamp Pharma Corporation2015-09-08Not applicableCanada
Jamp-ramiprilCapsule5 mgOralJamp Pharma Corporation2010-03-10Not applicableCanada
Mar-ramiprilCapsule5.0 mgOralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mar-ramiprilCapsule10.0 mgOralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mar-ramiprilCapsule1.25 mgOralMarcan Pharmaceuticals Inc2015-06-17Not applicableCanada
Mar-ramiprilCapsule15.0 mgOralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-ramiprilCapsule2.5 mgOralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mint-ramiprilCapsule2.5 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilCapsule1.25 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-ramiprilCapsule5.0 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilCapsule10.0 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilCapsule15.0 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mylan-ramiprilCapsule1.25 mgOralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilCapsule2.5 mgOralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilCapsule5.0 mgOralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilCapsule10 mgOralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
PMS-ramiprilCapsule10 mgOralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilCapsule15 mgOralPharmascience Inc2010-05-11Not applicableCanada
PMS-ramiprilCapsule2.5 mgOralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilCapsule1.25 mgOralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilCapsule5 mgOralPharmascience Inc2009-10-06Not applicableCanada
Priva-ramiprilCapsule2.5 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-ramiprilCapsule5 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-ramiprilCapsule10 mgOralPharmapar IncNot applicableNot applicableCanada
Pro-ramipril - 1.25Capsule1.25 mgOralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 10Capsule10 mgOralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 2.5Capsule2.5 mgOralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 5Capsule5 mgOralPro Doc Limitee2011-11-25Not applicableCanada
RamaceTablet1.25 mgOralSanofi Aventis Canada IncNot applicableNot applicableCanada
RamaceTablet2.5 mgOralSanofi Aventis Canada IncNot applicableNot applicableCanada
RamaceTablet5 mgOralSanofi Aventis Canada IncNot applicableNot applicableCanada
RamaceTablet10 mgOralSanofi Aventis Canada IncNot applicableNot applicableCanada
RamiprilCapsule10 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
RamiprilCapsule5 mgOralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
RamiprilCapsule2.5 mgOralLaboratoire Riva Inc2008-03-14Not applicableCanada
RamiprilCapsule1.25 mgOralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
RamiprilCapsule1.25 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
RamiprilCapsule2.5 mgOralSanis Health Inc2011-11-24Not applicableCanada
RamiprilCapsule10 mgOralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
RamiprilCapsule5 mgOralLaboratoire Riva Inc2008-03-14Not applicableCanada
RamiprilCapsule2.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
RamiprilCapsule5 mgOralSanis Health Inc2011-11-24Not applicableCanada
RamiprilCapsule10 mgOralLaboratoire Riva Inc2008-03-14Not applicableCanada
RamiprilCapsule5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
RamiprilCapsule10 mgOralSanis Health Inc2011-11-24Not applicableCanada
RamiprilCapsule1.25 mgOralLaboratoire Riva Inc2008-03-17Not applicableCanada
RamiprilCapsule2.5 mgOralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramipril CapsulesCapsule1.25 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril CapsulesCapsule2.5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril CapsulesCapsule5.0 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril CapsulesCapsule10.0 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril-10Capsule10 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ramipril-2.5Capsule2.5 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ramipril-5Capsule5 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ran-ramiprilCapsule15 mgOralRanbaxy Pharmaceuticals Canada Inc.2014-11-24Not applicableCanada
Ran-ramiprilCapsule5 mgOralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilCapsule2.5 mgOralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilCapsule10 mgOralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilCapsule1.25 mgOralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ratio-ramiprilCapsule2.5 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilCapsule5.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilCapsule10.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilCapsule15 mgOralRatiopharm Inc Division Of Teva Canada Limited2009-05-052014-09-19Canada
Ratio-ramiprilCapsule1.25 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Rbx-ramiprilCapsule10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilCapsule1.25 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilCapsule2.5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilCapsule5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Sandoz RamiprilTablet5 mgOralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz RamiprilTablet10 mgOralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz RamiprilTablet1.25 mgOralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz RamiprilTablet2.5 mgOralSandoz Canada Incorporated2007-07-05Not applicableCanada
Teva-ramiprilCapsule2.5 mgOralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilCapsule5 mgOralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilCapsule1.25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-ramiprilCapsule10 mgOralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilCapsule15 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Van-ramiprilCapsule10 mgOralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilCapsule1.25 mgOralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilCapsule15 mgOralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilCapsule2.5 mgOralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilCapsule5 mgOralVanc Pharmaceuticals Inc2016-02-12Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ramiprilCapsule10 mgOralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilCapsule1.25 mgOralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilCapsule15 mgOralApotex Inc2009-05-01Not applicableCanada
Apo-ramiprilCapsule2.5 mgOralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilCapsule5 mgOralApotex Inc2006-12-12Not applicableCanada
RamiprilCapsule10 mg/1OralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
RamiprilCapsule10 mg/1OralA S Medication Solutions2015-02-12Not applicableUs
RamiprilCapsule1.25 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
RamiprilCapsule10 mg/1OralActavis Pharma, Inc.2007-12-26Not applicableUs
RamiprilCapsule5 mg/1OralApotex Corp.2008-06-20Not applicableUs
RamiprilCapsule5 mg/1OralAurobindo Pharma Limited2011-06-08Not applicableUs
RamiprilCapsule10 mg/1OralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
RamiprilCapsule10 mg/1OralPhysicians Total Care, Inc.2008-02-21Not applicableUs
RamiprilCapsule2.5 mg/1OralAmerican Health Packaging2008-01-22Not applicableUs
RamiprilCapsule5 mg/1OralAccord Healthcare Inc.2014-07-01Not applicableUs
RamiprilCapsule2.5 mg/1OralTeva Pharmaceuticals USA Inc2008-06-242016-07-31Us
RamiprilCapsule5 mg/1OralA S Medication Solutions2015-02-12Not applicableUs
RamiprilCapsule5 mg/1OralCardinal Health2008-06-18Not applicableUs
RamiprilCapsule5 mg/1Oralbryant ranch prepack2008-06-18Not applicableUs
RamiprilCapsule1.25 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
RamiprilCapsule10 mg/1OralMedsource Pharmaceuticals2008-06-18Not applicableUs
RamiprilCapsule5 mg/1OralProficient Rx LP2008-06-10Not applicableUs
RamiprilCapsule2.5 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
RamiprilCapsule2.5 mg/1OralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
RamiprilCapsule5 mg/1OralWest Ward Pharmaceuticals Corp.2008-06-18Not applicableUs
RamiprilCapsule10 mg/1OralCitron Pharma LLC2011-06-08Not applicableUs
RamiprilCapsule5 mg/1OralAidarex Pharmaceuticals LLC2011-06-08Not applicableUs
RamiprilCapsule10 mg/1OralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
RamiprilCapsule10 mg/1OralCadila Healthcare Limited2010-11-20Not applicableUs
RamiprilCapsule1.25 mg/1OralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
RamiprilTablet5 mg/1OralNorthwind Pharmaceuticals2014-12-30Not applicableUs
RamiprilCapsule1.25 mg/1OralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
RamiprilCapsule10 mg/1OralA S Medication Solutions2011-06-08Not applicableUs
RamiprilCapsule5 mg/1OralAtlantic Biologicals Corps2008-06-18Not applicableUs
RamiprilCapsule1.25 mg/1OralActavis Pharma, Inc.2007-12-26Not applicableUs
RamiprilCapsule5 mg/1OralProficient Rx LP2007-12-26Not applicableUs
RamiprilCapsule1.25 mg/1OralCitron Pharma LLC2011-06-08Not applicableUs
RamiprilCapsule2.5 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
RamiprilCapsule10 mg/1OralApotex Corp.2008-06-20Not applicableUs
RamiprilCapsule10 mg/1OralAurobindo Pharma Limited2011-06-08Not applicableUs
RamiprilCapsule2.5 mg/1OralPhysicians Total Care, Inc.2008-02-13Not applicableUs
RamiprilCapsule5 mg/1OralAmerican Health Packaging2008-01-22Not applicableUs
RamiprilCapsule10 mg/1OralAccord Healthcare Inc.2014-07-01Not applicableUs
RamiprilCapsule5 mg/1OralTeva Pharmaceuticals USA Inc2008-06-242016-03-31Us
RamiprilCapsule5 mg/1OralDIRECT RX2014-01-01Not applicableUs
RamiprilCapsule1.25 mg/1OralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
RamiprilCapsule1.25 mg/1OralCadila Healthcare Limited2010-11-20Not applicableUs
RamiprilCapsule2.5 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
RamiprilCapsule10 mg/1OralREMEDYREPACK INC.2011-08-222016-10-13Us
RamiprilCapsule10 mg/1OralProficient Rx LP2008-06-10Not applicableUs
RamiprilCapsule5 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
RamiprilCapsule5 mg/1OralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
RamiprilCapsule10 mg/1OralWest Ward Pharmaceuticals Corp.2008-06-18Not applicableUs
RamiprilCapsule5 mg/1OralRebel Distributors Corp2007-12-26Not applicableUs
RamiprilCapsule10 mg/1OralAidarex Pharmaceuticals LLC2011-06-08Not applicableUs
RamiprilCapsule2.5 mg/1OralRebel Distributors Corp2007-12-26Not applicableUs
RamiprilCapsule2.5 mg/1OralActavis Pharma, Inc.2007-12-26Not applicableUs
RamiprilCapsule1.25 mg/1OralApotex Corp.2008-06-20Not applicableUs
RamiprilCapsule1.25 mg/1OralAurobindo Pharma Limited2011-06-08Not applicableUs
RamiprilCapsule2.5 mg/1OralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
RamiprilCapsule10 mg/301OralNorthwind Pharmaceuticals2014-05-07Not applicableUs
RamiprilCapsule2.5 mg/1OralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
RamiprilCapsule2.5 mg/1OralA S Medication Solutions2008-06-18Not applicableUs
RamiprilCapsule1.25 mg/1OralPhysicians Total Care, Inc.2008-07-14Not applicableUs
RamiprilCapsule1.25 mg/1OralWest Ward Pharmaceuticals Corp.2008-06-18Not applicableUs
RamiprilCapsule2.5 mg/1OralCitron Pharma LLC2011-06-08Not applicableUs
RamiprilCapsule5 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
RamiprilCapsule5 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
RamiprilCapsule1.25 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
RamiprilCapsule2.5 mg/1OralCadila Healthcare Limited2010-11-20Not applicableUs
RamiprilCapsule5 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
RamiprilCapsule5 mg/1OralUnit Dose Services2008-06-24Not applicableUs
RamiprilCapsule10 mg/1OralAmerican Health Packaging2008-01-22Not applicableUs
RamiprilCapsule2.5 mg/1OralPd Rx Pharmaceuticals, Inc.2008-06-10Not applicableUs
RamiprilCapsule10 mg/1OralTeva Pharmaceuticals USA Inc2008-06-242016-03-31Us
RamiprilCapsule10 mg/1OralDIRECT RX2015-01-01Not applicableUs
RamiprilCapsule2.5 mg/1OralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
RamiprilCapsule10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-02-12Not applicableUs
RamiprilCapsule10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2008-06-24Not applicableUs
RamiprilCapsule2.5 mg/1OralProficient Rx LP2008-06-10Not applicableUs
RamiprilCapsule1.25 mg/1OralCarilion Materials Management2008-06-18Not applicableUs
RamiprilCapsule, gelatin coated10 mg/1OralDIRECT RX2016-01-13Not applicableUs
RamiprilCapsule10 mg/1OralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
RamiprilCapsule1.25 mg/1OralAccord Healthcare Inc.2014-07-01Not applicableUs
RamiprilCapsule5 mg/1OralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
RamiprilCapsule5 mg/1OralA S Medication Solutions2015-02-12Not applicableUs
RamiprilCapsule10 mg/1OralRebel Distributors Corp2007-12-26Not applicableUs
RamiprilCapsule5 mg/1OralActavis Pharma, Inc.2007-12-26Not applicableUs
RamiprilCapsule2.5 mg/1OralApotex Corp.2008-06-20Not applicableUs
RamiprilCapsule2.5 mg/1OralAurobindo Pharma Limited2011-06-08Not applicableUs
RamiprilCapsule5 mg/1OralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
RamiprilCapsule5 mg/1OralPhysicians Total Care, Inc.2009-07-30Not applicableUs
RamiprilCapsule10 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
RamiprilCapsule10 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
RamiprilCapsule1.25 mg/1OralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
RamiprilCapsule2.5 mg/1OralWest Ward Pharmaceuticals Corp.2008-06-18Not applicableUs
RamiprilCapsule5 mg/1OralCitron Pharma LLC2011-06-08Not applicableUs
RamiprilCapsule10 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
RamiprilCapsule5 mg/1OralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
RamiprilCapsule5 mg/1OralCadila Healthcare Limited2010-11-20Not applicableUs
RamiprilCapsule10 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
RamiprilCapsule10 mg/1OralUnit Dose Services2008-06-242016-03-31Us
RamiprilCapsule1.25 mg/1OralAmerican Health Packaging2008-06-09Not applicableUs
RamiprilCapsule5 mg/1OralA S Medication Solutions2011-06-08Not applicableUs
RamiprilCapsule10 mg/1OralBlenheim Pharmacal, Inc.2014-01-13Not applicableUs
RamiprilCapsule10 mg/1OralPreferred Pharmaceuticals Inc.2016-11-07Not applicableUs
RamiprilCapsule2.5 mg/1OralAccord Healthcare Inc.2014-07-01Not applicableUs
RamiprilCapsule10 mg/1OralA S Medication Solutions2015-02-12Not applicableUs
RamiprilCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.2008-06-09Not applicableUs
RamiprilCapsule10 mg/1Oralbryant ranch prepack2009-05-05Not applicableUs
RamiprilCapsule10 mg/1OralDispensing Solutions, Inc.2008-06-18Not applicableUs
RamiprilCapsule2.5 mg/1OralProficient Rx LP2015-02-12Not applicableUs
RamiprilCapsule2.5 mg/1OralCardinal Health2008-06-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcovilSanofi-Aventis (Spain)
CaraselAlmirall (Spain)
CardaceSanofi-Aventis (Finland), Aventis (India), Aventis (Indonesia)
DelixAventis (Germany, Turkey),
HyprenAstraZeneca (Austria)
LostapresTemis (Argentina)
PramaceAstra (Ireland), AstraZeneca (Sweden)
QuarkPolifarma (Italy)
TriatecSanofi-Aventis (Brazil, Chili, Denmark, France, Greece, Indonesia, Italy,Norway, Portugal, Sweden, Switzerland)
TritaceSanofi-Aventis (Argentina, Australia, Austria, Belgium, Czech Republic, Hong Kong, Hungary, Ireland, Israel, Malaysia, Mexico, Netherlands, Poland, Singapor, Thailand, United Kingdom), Aventis (New Zealand, Philippines, South Africa)
VesdilAstraZeneca (Germany), Promed (Germany)
Brand mixtures
NameLabellerIngredients
Altace HctValeant Canada Lp Valeant Canada S.E.C.
Altace Plus Felodipine 2.5mg + 2.5mgSanofi Aventis Canada Inc
Altace Plus Felodipine 5mg + 5mgSanofi Aventis Canada Inc
Apo-ramipril/hctzApotex Inc
PMS-ramipril-hctzPharmascience Inc
Ramipril-hctzSanis Health Inc
Ran-ramipril HctzRanbaxy Pharmaceuticals Canada Inc.
Teva-ramipril/hctzTeva Canada Limited
SaltsNot Available
Categories
UNIIL35JN3I7SJ
CAS number87333-19-5
WeightAverage: 416.5106
Monoisotopic: 416.231122144
Chemical FormulaC23H32N2O5
InChI KeyHDACQVRGBOVJII-JBDAPHQKSA-N
InChI
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
IUPAC Name
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid
SMILES
[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[[email protected]](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Pharmacology
IndicationFor the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.
Structured Indications
PharmacodynamicsRamipril is an ACE inhibitor similar to benazepril, fosinopril and quinapril. It is an inactive prodrug that is converted to ramiprilat in the liver, the main site of activation, and kidneys. Ramiprilat confers blood pressure lowing effects by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of ramiprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Ramiprilat, the principle active metabolite of ramipril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Ramipril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
AbsorptionThe extent of absorption is at least 50-60%. Food decreases the rate of absorption from the GI tract without affecting the extent of absorption. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when oral administration was compared to intravenous administration.
Volume of distributionNot Available
Protein bindingProtein binding of ramipril is about 73% and that of ramiprilat about 56%.
Metabolism

Hepatic metabolism accounts for 75% of total ramipril metabolism. 25% of hepatic metabolism produces the active metabolite ramiprilat via liver esterase enzymes. 100% of renal metabolism converts ramipril to ramiprilat. Other metabolites, diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, are inactive.

SubstrateEnzymesProduct
Ramipril
Not Available
Diketopiperazine acidDetails
Ramipril
Not Available
Diketopiperazine esterDetails
Ramipril
RamiprilatDetails
Route of eliminationNot Available
Half lifePlasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.
ClearanceNot Available
ToxicitySymptoms of overdose may include excessive peripheral vasodilation (with marked hypotension and shock), bradycardia, electrolyte disturbances, and renal failure. The most likely adverse reactions are symptoms attributable to its blood-pressure lowing effect. May cause headache, dizziness, asthenia, chest pain, nausea, peripheral edema, somnolence, impotence, rash, arthritis, and dyspnea. LD50 = 10933 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ramipril Action PathwayDrug actionSMP00154
Ramipril Metabolism PathwayDrug metabolismSMP00597
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4344 Not AvailableA Allele, homozygoteMore rapid response to drug treatment17885551
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4344 Not AvailableG Allele, homozygoteMore rapid response to drug treatment17885551
Angiotensin-converting enzyme 2
Gene symbol: ACE2
UniProt: Q9BYF1
rs4344 Not AvailableG > AThose with the AA or GG gentypes respond better to treatment17885551
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Ramipril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ramipril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Ramipril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Ramipril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Ramipril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Ramipril is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ramipril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Ramipril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Ramipril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Ramipril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ramipril.Approved, Illicit, Investigational
AlprenololRamipril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanRamipril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Ramipril.Experimental
AmifostineRamipril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Ramipril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Ramipril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Ramipril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Ramipril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Ramipril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ramipril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Ramipril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Ramipril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Ramipril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Ramipril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Ramipril is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Ramipril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Ramipril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Ramipril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Ramipril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Ramipril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Ramipril is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Ramipril is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Ramipril is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ramipril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Azapropazone.Withdrawn
AzathioprineRamipril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ramipril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ramipril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Ramipril.Experimental
BarbitalBarbital may increase the hypotensive activities of Ramipril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Ramipril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Ramipril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Benoxaprofen.Withdrawn
BepridilRamipril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Ramipril is combined with Betaxolol.Approved
BethanidineRamipril may increase the hypotensive activities of Bethanidine.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Ramipril is combined with Betulinic Acid.Investigational
BimatoprostRamipril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Ramipril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Ramipril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Ramipril is combined with Bortezomib.Approved, Investigational
BosentanRamipril may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Ramipril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Ramipril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ramipril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Ramipril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Ramipril is combined with Bupivacaine.Approved, Investigational
BupranololRamipril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ramipril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Ramipril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Ramipril.Approved
CandoxatrilRamipril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Captopril.Approved
CarbamazepineThe metabolism of Ramipril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Ramipril is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Ramipril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Ramipril is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Ramipril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Ramipril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Celecoxib.Approved, Investigational
CeliprololRamipril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Ramipril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Ramipril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Ramipril.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorthalidone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Cilnidipine.Approved
CiprofloxacinRamipril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ramipril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ramipril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Ramipril is combined with Clofarabine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ramipril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Ramipril is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Ramipril is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Ramipril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Ramipril.Approved
CryptenamineRamipril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Ramipril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ramipril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ramipril.Approved, Investigational, Vet Approved
CyclothiazideRamipril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Ramipril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Ramipril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Ramipril.Investigational
DebrisoquinRamipril may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ramipril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Ramipril.Investigational
DeserpidineRamipril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Ramipril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Ramipril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Ramipril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Ramipril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ramipril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Ramipril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ramipril.Approved
DihydralazineRamipril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ramipril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Ramipril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Ramipril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Dipyridamole.Approved
DorzolamideRamipril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Ramipril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Ramipril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ramipril.Approved
DrospirenoneRamipril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Droxicam.Approved
DuloxetineRamipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Ramipril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Ramipril.Approved
E6201The risk or severity of adverse effects can be increased when Ramipril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ramipril is combined with Ebselen.Investigational
EfonidipineRamipril may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Enalapril.Approved, Vet Approved
EnalaprilatRamipril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Ramipril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Ramipril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Ramipril.Approved
EpoprostenolRamipril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ramipril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ramipril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ramipril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ramipril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Ramipril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Ramipril is combined with Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Ramipril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Ramipril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Ramipril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Ramipril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Ramipril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ramipril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Ramipril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Ramipril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Ramipril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Ramipril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramipril.Approved
exisulindThe risk or severity of adverse effects can be increased when Ramipril is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Ramipril is combined with Fenbufen.Approved
FenoldopamRamipril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Ramipril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Ramipril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Ramipril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ramipril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Ramipril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Ramipril can be decreased when it is combined with Garlic.Approved
GuanabenzRamipril may increase the hypotensive activities of Guanabenz.Approved
GuanadrelRamipril may increase the hypotensive activities of Guanadrel.Approved
GuanethidineRamipril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Ramipril is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Ramipril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Ramipril.Approved, Investigational
HexamethoniumRamipril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Ramipril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Ramipril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Ramipril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Ramipril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Ramipril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideRamipril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ramipril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Ramipril.Approved
IloprostIloprost may increase the hypotensive activities of Ramipril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ramipril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Indapamide.Approved
IndenololRamipril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Ramipril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Indoprofen.Withdrawn
IndoraminRamipril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Ramipril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Ramipril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ramipril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Ramipril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Ramipril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Ramipril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Isradipine.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Kebuzone.Experimental
KetanserinRamipril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Ramipril is combined with Labetalol.Approved
LacidipineRamipril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Ramipril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostRamipril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Ramipril is combined with Leflunomide.Approved, Investigational
LercanidipineRamipril may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Ramipril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Ramipril is combined with Levobupivacaine.Approved
LevodopaRamipril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Ramipril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Ramipril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Ramipril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Ramipril.Approved
LofexidineRamipril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Ramipril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ramipril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Lumiracoxib.Approved, Investigational
MacitentanRamipril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ramipril is combined with Magnesium salicylate.Approved
ManidipineRamipril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Ramipril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Ramipril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Ramipril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Ramipril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Ramipril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Ramipril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Ramipril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Ramipril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Ramipril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Ramipril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Ramipril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Ramipril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Ramipril is combined with Metoprolol.Approved, Investigational
MetyrosineRamipril may increase the hypotensive activities of Metyrosine.Approved
MibefradilRamipril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ramipril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Ramipril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Ramipril is combined with Minoxidil.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ramipril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Ramipril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Ramipril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Ramipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Ramipril is combined with Morphine.Approved, Investigational
MoxonidineRamipril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Ramipril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Ramipril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Ramipril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Ramipril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Ramipril is combined with Naftifine.Approved
NaftopidilRamipril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Ramipril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Ramipril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Ramipril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ramipril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Ramipril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Ramipril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Ramipril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Ramipril is combined with Niflumic Acid.Approved
NiguldipineRamipril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineRamipril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Nisoldipine.Approved
NitrendipineRamipril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Ramipril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitroprusside.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ramipril.Approved
ObinutuzumabRamipril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Ramipril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ramipril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ramipril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Olsalazine.Approved
OmapatrilatRamipril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Ramipril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Ramipril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxaprozin.Approved
OxprenololRamipril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Ramipril is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Ramipril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Ramipril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Ramipril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Ramipril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Ramipril.Approved, Vet Approved
PentoliniumRamipril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Ramipril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Ramipril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Ramipril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Ramipril.Approved
PhenoxybenzamineRamipril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Ramipril.Withdrawn
PhentolamineRamipril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Ramipril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ramipril.Approved
PinacidilRamipril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Ramipril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Ramipril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Ramipril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Ramipril.Withdrawn
PolythiazideRamipril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Ramipril is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Ramipril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Ramipril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Ramipril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Ramipril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Ramipril is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Ramipril.Approved
PTC299The risk or severity of adverse effects can be increased when Ramipril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Ramipril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Ramipril.Approved
QuinineQuinine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Ramipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Ramipril is combined with Remifentanil.Approved
RemikirenRamipril may increase the hypotensive activities of Remikiren.Approved
RescinnamineRamipril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Ramipril is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Ramipril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Ramipril.Approved
RilmenidineRamipril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ramipril.Approved
RisperidoneRamipril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabRamipril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ramipril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ramipril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ramipril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Ramipril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Ramipril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Ramipril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Ramipril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ramipril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ramipril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Ramipril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Ramipril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Ramipril.Approved, Investigational, Vet Approved
SelexipagRamipril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Ramipril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Ramipril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ramipril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ramipril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ramipril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Ramipril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Ramipril.Approved, Investigational
SitaxentanRamipril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Ramipril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Ramipril is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Ramipril is combined with Sotalol.Approved
SpiraprilRamipril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Ramipril is combined with SRT501.Investigational
St. John's WortThe metabolism of Ramipril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Ramipril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Ramipril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ramipril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Ramipril.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Ramipril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ramipril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.Approved, Investigational
TemocaprilRamipril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Ramipril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Ramipril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Ramipril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Ramipril is combined with Teriflunomide.Approved
TerlipressinRamipril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Ramipril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Ramipril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Ramipril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Ramipril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Ramipril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Tiaprofenic acid.Approved
TiboloneRamipril may increase the hypotensive activities of Tibolone.Approved
TicrynafenRamipril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Ramipril is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Ramipril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Ramipril.Approved
TipranavirThe serum concentration of Ramipril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Ramipril.Approved
TolazolineRamipril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Ramipril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Ramipril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Ramipril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ramipril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Ramipril.Approved
TravoprostRamipril may increase the hypotensive activities of Travoprost.Approved
TreprostinilRamipril may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Ramipril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Ramipril is combined with Triamterene.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ramipril.Approved
TrichlormethiazideRamipril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinRamipril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanRamipril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Ramipril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ramipril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Ramipril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Ramipril.Approved, Investigational
UnoprostoneRamipril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ramipril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Ramipril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Ramipril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Ramipril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Ramipril.Approved, Investigational
VinpocetineRamipril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineRamipril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Ramipril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Ramipril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Ramipril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Ramipril is combined with Zomepirac.Withdrawn
Food Interactions
  • Alcohol may increase the vasodilatory effects of ramipril.
  • Herbs that may attenuate the antihypertensive effect of ramipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of ramipril.
  • Ramipril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Take without regard to meals.
References
Synthesis Reference

Edward Wilson, Martin Beasley, “Stabilized ramipril compositions and methods of making.” U.S. Patent US20060134213, issued June 22, 2006.

US20060134213
General References
  1. Cacciapuoti F, Capasso A, Mirra G, De Nicola A, Minicucci F, Gentile S: Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. Int J Cardiol. 1998 Jan 31;63(2):175-8. [PubMed:9510492 ]
  2. Kleinert S: HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet. 1999 Sep 4;354(9181):841. [PubMed:10485736 ]
External Links
ATC CodesC10BX04C09AA05C10BX06C09BA05C09BB07C09BB05
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSDownload (53.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9159
Blood Brain Barrier-0.8726
Caco-2 permeable-0.8491
P-glycoprotein substrateSubstrate0.7263
P-glycoprotein inhibitor INon-inhibitor0.7002
P-glycoprotein inhibitor IIInhibitor0.6295
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.8541
CYP450 2D6 substrateNon-substrate0.8969
CYP450 3A4 substrateNon-substrate0.5082
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9304
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5691
Ames testNon AMES toxic0.9108
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8903
Rat acute toxicity1.6732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Non-inhibitor0.7901
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Actavis elizabeth llc
  • Apotex inc
  • Cipla ltd
  • Dr reddys laboratories ltd
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • King Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
CapsuleOral1.25 mg
CapsuleOral15 mg
CapsuleOral10.0 mg
CapsuleOral15.0 mg
CapsuleOral5.0 mg
CapsuleOral10 mg
CapsuleOral2.5 mg
CapsuleOral5 mg
TabletOral
CapsuleOral1.25 mg/1
CapsuleOral10 mg/1
CapsuleOral10 mg/301
CapsuleOral2.5 mg/1
CapsuleOral5 mg/1
Capsule, gelatin coatedOral10 mg/1
TabletOral5 mg/1
TabletOral1.25 mg
TabletOral10 mg
TabletOral2.5 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Altace 10 mg capsule2.87USD capsule
Altace 2.5 mg capsule2.54USD capsule
Altace 5 mg capsule2.53USD capsule
Altace 10 mg tablet2.37USD tablet
Altace 1.25 mg capsule2.2USD capsule
Ramipril 10 mg capsule2.19USD capsule
Altace 5 mg tablet2.02USD tablet
Altace 2.5 mg tablet1.93USD tablet
Ramipril 5 mg capsule1.87USD capsule
Ramipril 2.5 mg capsule1.78USD capsule
Altace 1.25 mg tablet1.63USD tablet
Ramipril 1.25 mg capsule1.59USD capsule
Altace 10 mg Tablet1.14USD tablet
Altace 2.5 mg Tablet0.9USD tablet
Altace 5 mg Tablet0.9USD tablet
Altace 1.25 mg Tablet0.78USD tablet
Apo-Ramipril 10 mg Tablet0.64USD tablet
Co Ramipril 10 mg Tablet0.64USD tablet
Jamp-Ramipril 10 mg Tablet0.64USD tablet
Mylan-Ramipril 10 mg Tablet0.64USD tablet
Novo-Ramipril 10 mg Tablet0.64USD tablet
Pms-Ramipril 10 mg Tablet0.64USD tablet
Ramipril 10 mg Tablet0.64USD tablet
Ran-Ramipril 10 mg Tablet0.64USD tablet
Ratio-Ramipril 10 mg Tablet0.64USD tablet
Sandoz Ramipril 10 mg Tablet0.64USD tablet
Apo-Ramipril 2.5 mg Tablet0.5USD tablet
Apo-Ramipril 5 mg Tablet0.5USD tablet
Co Ramipril 2.5 mg Tablet0.5USD tablet
Co Ramipril 5 mg Tablet0.5USD tablet
Jamp-Ramipril 2.5 mg Tablet0.5USD tablet
Jamp-Ramipril 5 mg Tablet0.5USD tablet
Mylan-Ramipril 2.5 mg Tablet0.5USD tablet
Mylan-Ramipril 5 mg Tablet0.5USD tablet
Novo-Ramipril 2.5 mg Tablet0.5USD tablet
Novo-Ramipril 5 mg Tablet0.5USD tablet
Pms-Ramipril 2.5 mg Tablet0.5USD tablet
Pms-Ramipril 5 mg Tablet0.5USD tablet
Ramipril 2.5 mg Tablet0.5USD tablet
Ramipril 5 mg Tablet0.5USD tablet
Ran-Ramipril 2.5 mg Tablet0.5USD tablet
Ran-Ramipril 5 mg Tablet0.5USD tablet
Ratio-Ramipril 2.5 mg Tablet0.5USD tablet
Ratio-Ramipril 5 mg Tablet0.5USD tablet
Sandoz Ramipril 2.5 mg Tablet0.5USD tablet
Sandoz Ramipril 5 mg Tablet0.5USD tablet
Apo-Ramipril 1.25 mg Tablet0.44USD tablet
Co Ramipril 1.25 mg Tablet0.44USD tablet
Jamp-Ramipril 1.25 mg Tablet0.44USD tablet
Mylan-Ramipril 1.25 mg Tablet0.44USD tablet
Pms-Ramipril 1.25 mg Tablet0.44USD tablet
Ramipril 1.25 mg Tablet0.44USD tablet
Ran-Ramipril 1.25 mg Tablet0.44USD tablet
Ratio-Ramipril 1.25 mg Tablet0.44USD tablet
Sandoz Ramipril 1.25 mg Tablet0.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1338344 No1996-05-212013-05-21Canada
CA2382387 No2005-06-212020-08-25Canada
US5403856 No1995-04-042012-04-04Us
US7368469 No2000-08-302020-08-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point109 °CPhysProp
water solubility3.5mg/LNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.039 mg/mLALOGPS
logP0.92ALOGPS
logP1.47ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.75ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity111.19 m3·mol-1ChemAxon
Polarizability44.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Levitt DG, Schoemaker RC: Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. BMC Clin Pharmacol. 2006 Jan 6;6:1. [PubMed:16398929 ]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Shah GB, Sharma S, Mehta AA, Goyal RK: Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000 Aug;36(2):169-75. [PubMed:10942157 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:41